Description of the upcoming change in data analysis for USP dissolution performance verification tests

Walter W. Hauck, Anthony J. DeStefano, William E. Brown, Erika Stippler, Darrell R. Abernethy, Roger L. Williams, Thomas S. Foster, James E. Polli, Diane J. Burgess, G. Bryan Crist, Mario A. Gonzalez, Vivian A. Gray, Johannes Kraemer, Lewis J. Leeson, Alan F. Parr, Leon Shargel, Eli Shefter, W. Craig Simon, Nhan L. Tran, Clarence T. Ueda

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

As part of its evaluation of the performance verification tests used periodically to affirm the integrity of the USP Performance test when General Chapter Dissolution <711> is relied upon, the Biopharmaceutics Expert Committee of the Council of Experts, working with staff, decided to change the form of the accept/reject decision from one based on the result for each tablet to one based on the mean and coefficient of variation of results from a set of tablets. This paper describes the new approach. The paper also describes an implementation period for the approach, coupled with a period during which USP will discontinue use of the Salicylic Acid tablet in a performance verification test.

Original languageEnglish (US)
Pages (from-to)7-12
Number of pages6
JournalDissolution Technologies
Volume16
Issue number1
DOIs
StatePublished - Feb 2009
Externally publishedYes

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Description of the upcoming change in data analysis for USP dissolution performance verification tests'. Together they form a unique fingerprint.

Cite this